Keywords
Cirrhosis
Portal Hypertension
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the effectiveness of the use of non-selective beta-blockers (NBSBs) in the treatment of patients with liver cirrhosis, including complications such as portal hypertension and esophageal variceal bleeding. Methods: Integrative bibliographic review in PubMed Central (PMC) using the search strategy: (("Adrenergic beta-Antagonists"[MeSH]) OR (Nonselective beta-blockers) OR (Non-Selective Beta-Blockers) OR (Non-Selective β-Blockers) OR (Beta-Blockers) OR (β-Blockers)) AND ((Chirrosis) OR ("Hypertension, Portal"[MeSH])). After the initial search, 174 studies were identified and subjected to selection criteria. After applying inclusion and exclusion criteria, 14 articles were selected to make up this study. Results: The two main approaches to preventing complications arising from cirrhosis were analyzed, pharmacological intervention with BBNS, which has been shown to significantly reduce the chance of adverse events compared to the approach without such intervention; and the administration of Non-Selective Beta Blockers, which was associated with this risk reduction, being influenced by factors such as greater treatment efficacy, as well as reducing unfavorable events and preventing complications arising from the disease. Final considerations: Studies suggest greater efficacy when using such interventions, however, more research is still needed to ensure complete harm reduction for these patients.
References
ABRALDES JG, et al. Update in the Treatment of the Complications of Cirrhosis. Clinical Gastroenterology and Hepatology, 2023; 21(8): 2100-2109.
ARDEVOL A, et al.Early rebleeding increases mortality of variecal bleeders on secondary prophylaxis with β-blockers and ligation." Digestive and Liver Disease, 2020; 52(9): 1017-1025.
BULTAS AC, et al. Use of nonselective β-blockers in patients with end-stage liver disease and select complications. Annals of Pharmacotherapy, 2020; 54(6): 583-593.
GARBUZENKODV DV e AREFYEV NO. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literature. J Evid Based Med, 2020; 13(4): 313-324.
HOFER BS, et al. Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis." Hepatology Communications, 2022; 6(9): 2569-2580.
JACHS M e REIBERGER T. Prevention of variceal bleeding and rebleeding by nonselective beta-blockers: a tailored approach. Clinics in Liver Disease, 2021; 25(2): 311-326.
JACHS M, et al. Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis. Clinical Gastroenterology and Hepatology, 2023; 21: 2318–2326.
KANG SH, et al. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study. Hepatology International, 2021; 15: 424-436.
KIM HY, et al. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. J Hepatol, 2019; 70(3): 412-422.
KOCKERLING D, et al. Current and future pharmacological therapies for managing cirrhosis and its complications. World Journal of Gastroenterology, 2019; 25(8): 888.
LEVY S e SAMUEL D. Prevention of decompensation in cirrhosis: a new youth for β blockers. Lancet, 2019; 393(10181): 1571-1572.
MIAO Z, et al. Comparison of therapies for secondary prophylaxis of esophageal variceal bleeding in cirrhosis: a network meta-analysis of randomized controlled trials. Clinical Therapeutics, 2020; 42(7): 1246-1275.
PATERNOSTRO R, et al. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Digestive and Liver Disease, 2022; 54(4): 500-508.
SAUERBRUCH T, et al. "Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?." Frontiers in medicine, 2023; 9: 1100966.
TURCO L, et al. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. Liver International: Official Journal of the International Association for the Study of the Liver, 2023; 43: 1183 - 1194.
TURCO L, et al. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clin Gastroenterol Hepatol, 2020; 18(2): 313-327.e6.
VILLANUEVA C, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. The lancet, 2019; 393(10181): 1597-1608.
YOON KT, et al. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol. 2021; 27(3): 425-436.
ZACHARIAS AP, et al. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev, 2018; 10(10).
ZHANG F, et al. Dose-dependent effect of propranolol on the hemodynamic response in cirrhotic patients with gastroesophageal varices. Eur J Gastroenterol Hepatol, 2019; 31(3): 368-374.